Why did AstraZeneca stock fall on Bristol Myers merger talk reports?

AstraZeneca shares fell after reports of merger talks with Bristol Myers Squibb because investors focused on mega-merger risks rather than scale benefits. The article says concerns included integration risk, portfolio overlap, antitrust scrutiny, and the lack of disclosed deal terms or any confirmed merger filing.